Elica

Each g of Elica cream contains mometasone furoate 1 mg. It also contains the following excipients: White petrolatum, white wax, propylene glycol stearate, stearyl alcohol and ceteareth-20, hexylene glycol, titanium dioxide, aluminum starch octenylsuccinate, purified water and phosphoric acid to adjust the pH.
Each g of Elica ointment contains mometasone furoate 1 mg. It also contains the following excipients: Hexylene glycol, white wax, propylene glycol stearate, white petrolatum, purified water and phosphoric acid to adjust the pH.
Each g of Elica lotion contains mometasone furoate 1 mg. It also contains the following excipients: Isopropyl alcohol, hydroxypropyl cellulose, sodium phosphate monobasic monohydrate, propylene glycol, purified water and phosphoric acid if needed, to adjust the pH.

Mometasone furoate, a synthetic corticosteroid, exhibits anti-inflammatory, antipruritic and vasoconstrictive properties.

Relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses eg, psoriasis and atopic dermatitis.
Elica lotion may be applied to scalp lesions.

A thin film of Elica cream or ointment should be applied to the affected skin areas once daily.
Apply a few drops of Elica lotion to affected skin areas including scalp sites once daily; massage gently and thoroughly until the medication disappears.

Symptoms: Excessive, prolonged use of topical corticosteroids can suppress hypothalamic-pituitary-adrenal function resulting in secondary adrenal insufficiency.
Treatment: Appropriate symptomatic treatment is indicated. Acute hypercorticoid symptoms are virtually reversible. Treat electrolyte imbalance, if necessary. In cases of chronic toxicity, slow withdrawal of corticosteroids is advised. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.

Patients who are sensitive to mometasone furoate, to other corticosteroids or to any component of these preparations.

If irritation or sensitization develops with the use of Elica products, treatment should be discontinued and appropriate therapy instituted.
In the presence of an infection, use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection is controlled adequately.
Any of the side effects that have been reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.
Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Suitable precautions should be taken under these conditions or when long-term use is anticipated, particularly in infants and children.
Elica products are not for ophthalmic use.
Use in children: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with growth and development of children.

Since safe use of Elica products in pregnant women has not been established, topical corticosteroids should be used during pregnancy only if the potential benefit justifies potential risk to the fetus. Drugs of this class should not be used on pregnant patients in large amounts or for prolonged periods of time. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

The following local adverse reactions have been reported with mometasone furoate topical formulations: pruritis, application site reactions, bacterial infections, folliculitis, furunculosis, acneiform eruptions and signs of skin atrophy. Additional local adverse reactions that have been reported infrequently when topical dermatologic corticosteroids have been used as recommended include: burning, irritation, dryness, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, striae, miliaria. Systemic adverse reactions, such as blurred vision, have also been reported with the use of topical corticosteroids.

Store at temperature not exceeding 30°C.

Topical Corticosteroids

D07AC13 - mometasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.

Rx